Citius Oncology, Inc. CTOR Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period?
- Citius Oncology, Inc. (CTOR) reported share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period of 400K in Q3 2025.
- What does share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period mean?
- The total number of share-based payment awards, such as stock options, that were forfeited or expired during the reporting period due to non-vesting conditions or reaching the end of their contractual term. This metric helps investors understand the actual utilization of equity incentive plans.